Disclosed is a tramadol hydrochloride and paracetamol composition, comprising: about 2.5 to about 5 percent by weight of tramadol hydrochloride; about 25 to about 30 percent by weight of paracetamol; about 1.25 to about 1.75 percent by weight of colloidal silicon dioxide;about 0.25 to about 0.35 percent by weight of...

Disclosed is a voglibose orally disintegrating composition, comprising: about 0.1 to about 0.2 percent by weight of voglibose; about 70 to about 80 percent by weight of mannitol 200; about 0.25 to about 1 percent by weight of colloidal silicon dioxide; about 10 to about 20 percent by weight of mannitol 25; about 0.5...

Disclosed is a zolpidem composition and a process for preparing the same. The zolpidem composition comprises: zolpidem tartrate and polacrillin potassium in a weight ratio of 1:8. The process for preparation of a zolpidem composition comprises: mixing zolpidem tartrate and polacrillin potassium in a weight ratio of ...

An ophthalmic composition comprising a polyaphron dispersion.

A bioerodible patch comprising at least one bioadhesive layer and at least one non-bioadhesive layer, wherein the bioadhesive layer comprises at least one polyaphron dispersion and at least one bioadhesive polymer, and wherein the polyaphron dispersion comprises at least one pharmaceutically active agent. ...

A potyaphron dispersion comprising an external phase and potyaphrons having sn internal phase, the internal phase comprising (i) a fltst phase which is liquid and (ii) a second phase which is liquid orgascocs.

ABSTRACT PROCESS FOR PREPARATION OF MESALAMINE COMPOSITION AND MESALAMINE COMPOSITION THEREOF A process for preparation of a mesalamine composition, comprising: preparing a first drug layering suspension comprising mesalamine; performing a first drug layering in the fluid bed coater to form first drug layered ...

The present invention relates to a composition for topical application comprising: a first discontinuous phase comprising a first oil and tacrolimus; a second discontinuous phase comprising a second oil; and a continuous aqueous phase; wherein the first oil is different from the second oil.

A biliquid foam comprising from 10% to 98% by weight of a non-polar liquid other than a fuel and from 2 to 88% by weight of a continuous phase polar liquid comprising a C1-C4 alcohol, a liquid polyethylene glycol, ethylene glycol or propyleneglycol, or mixtures thereof, in an amount of at least 65% ...

An oral drug delivery system which comprises a biliquid foam comprising: from 1 to 20% by weight of a continuous hydrophilic phase, from 70 to 98% by weight of a pharmaceutically acceptable oil which forms a discontinuous phase, the said pharmaceutically acceptable oil having dissolved or dispersed therein a...

The present invention relates to a pharmaceutical composition comprising Racecadotril and co-crystallized sugar and a process or preparing the same.